Skip to main content
. 2013 Jan;98(1):87–94. doi: 10.3324/haematol.2012.067058

Figure 1.

Figure 1.

(A) Cumulative incidences of grade 3-4 hematologic adverse events and cumulative incidences of progression or death without adverse events in melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone (MP) treated patients. (B) Cumulative incidences of grade 3-4 non-hematologic adverse events and cumulative incidences of progression or death without adverse events in MPT and MP treated patients.